Search research articles
Contact Us
Filters
Showing results (51-60 of 65) with videos related to
Page
of 7
Sort By:
Frontiers in Nuclear Medicine
|
October 2, 2024
Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma
Vincent Rebière, Meriem Maajem, Ronan Le Calloch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2021
Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)
Isabelle Demeestere, Judith Racape, Julie Dechene, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2019
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
Guillaume Manson, Jean-Baptiste Mear, Charles Herbaux, et al.
Leukemia & Lymphoma
|
January 10, 2019
Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study
Driss Chaoui, Maya Hacini, Olivier Fitoussi, et al.
Hematological Oncology
|
July 5, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study
Nadia Younan, Carole Soussain, Sylvain Choquet, et al.
Leukemia
|
August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
The Lancet. Oncology
|
January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
René-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Haematologica
|
May 15, 2025
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study
Gabriel Brisou, Jérôme Paillassa, Sophie Bernard, et al.
The Lancet. Oncology
|
March 11, 2024
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
Arnon P Kater, Önder Arslan, Fatih Demirkan, et al.
Neuro-Oncology
|
March 9, 2016
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
Sophie Langner-Lemercier, Caroline Houillier, Carole Soussain, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 65) with videos related to
Sort By:
Page
of 7
Frontiers in Nuclear Medicine
|
October 2, 2024
Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma
Vincent Rebière, Meriem Maajem, Ronan Le Calloch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2021
Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011)
Isabelle Demeestere, Judith Racape, Julie Dechene, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2019
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
Guillaume Manson, Jean-Baptiste Mear, Charles Herbaux, et al.
Leukemia & Lymphoma
|
January 10, 2019
Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study
Driss Chaoui, Maya Hacini, Olivier Fitoussi, et al.
Hematological Oncology
|
July 5, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study
Nadia Younan, Carole Soussain, Sylvain Choquet, et al.
Leukemia
|
August 21, 2019
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Thierry Facon, Meletios A Dimopoulos, Nathalie Meuleman, et al.
The Lancet. Oncology
|
January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
René-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Haematologica
|
May 15, 2025
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study
Gabriel Brisou, Jérôme Paillassa, Sophie Bernard, et al.
The Lancet. Oncology
|
March 11, 2024
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial
Arnon P Kater, Önder Arslan, Fatih Demirkan, et al.
Neuro-Oncology
|
March 9, 2016
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
Sophie Langner-Lemercier, Caroline Houillier, Carole Soussain, et al.
Page
of 7